Daily Post Nigeria
Published
Nigeria’s number one contract farming company, Farm4Me has been named Africa’s Leading Quality Farm Equipment Sales & Rental Service Provider of the Year 2021.
Farm4Me bagged the award at the 7th African Quality Achievement Awards 2021 organized by World Quality Alliance held at Sheraton Hotels, Lagos on Friday 16th April, 2021.
This development came barely one month after the fast-growing agritech company was named the West Africa’s Best World Class Digital Agricultural Investment Platform Brand of the Year 2021 at the 10th West Africa Brand Excellence Award.
The African Quality Achievement Awards is an annual event aimed at celebrating leadership innovation and creativity in quality management in Africa.
Share this article
Share this article
HAIFA, Israel, April 20, 2021 /PRNewswire/ Elbit Systems Ltd. (NASDAQ: ESLT) (TASE: ESLT) ( Elbit Systems ) announced today that its U.S. subsidiary, Elbit Systems of America LLC, ( Elbit Systems of America ), was awarded a delivery order valued at approximately $41 million for the supply of night vision systems and various spare components to the U.S. Marine Corps. The order will be executed in Roanoke, Virginia and will be supplied through March 2022.
This order is part of a $249 million five-year Squad Binocular Night Vision Goggles Indefinite Delivery Indefinite Quantity (IDIQ) contract from September 6, 2019, under which the U.S. Marine Corps are supplied with Squad Binocular Night Vision Goggle ( SBNVG ) systems consisting of high-performance, white phosphor image intensifier binoculars, modular uncooled thermal imaging sensors and common external power supplies – providing Marines improved mobility and situational awareness during
Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a positive opinion on European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis from the European Medicines Agency Committee for Orphan Medicinal Products . The positive opinion issued by COMP will be …
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a positive opinion on European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
Share this article
Share this article
NEW YORK, April 20, 2021 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a positive opinion on European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
The positive opinion issued by COMP will be sent to the European Commission, which is expected to grant the orphan designation within 30 days. Under orphan designation in the European Union (EU), Seelos stands to benefit from several incentives such as protocol assistance, reduced regulatory fees and market exclusivity. European guidelines for Orphan Drug Designation are for diseases affecting not more than five in 10,000 people in the EU.
Armis and Eseye Provide Industry-First Synergy to Secure Connected Devices on Any Cellular Network
PALO ALTO, Calif. and GUILDFORD, United Kingdom, April 20, 2021 /PRNewswire/ Global connectivity specialist
Eseye, and leading agentless device security platform provider
Armis, today announced a strategic partnership and joint solution that enables organizations to deploy connected devices anywhere in the world with enterprise-class security and consistent, reliable cellular (4G/LTE/5G) connectivity.
Eseye s unique
Connectivity Management Platform enables devices to switch intelligently to any one of over 700 GSMA-compliant carriers to maximize uptime with greater than 98% global coverage. The
Armis Agentless Device Security Platform provides device discovery, monitoring, and behavioral risk assessments, and automatically responds to anomalies that put devices at risk. Together, this joint solution ensures organizations can deploy and access virtually any device globally w